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Summary 
A patient (OG) with Glanzmann thrombasthenia became refractory to platelet transfusion after 
the production of an immunoglobulin G (IgG) isoantibody (Abl) specific  for the integrin subunit 
/33. To determine the frequency at which the OG idiotype is found in the general population 
and in immune-mediated disease states, we developed a rabbit polyclonal antibody (Ab2) specific 
for affinity-purified OG anti-/33 Fab. The binding of Ab2 to Abl is inhibited by purified 0lI1b/33; 
Ab2 also binds to IgG specific for 0/Iib/33  obtained from one nonrelated Glanzmann throm- 
basthenia patient ES who has developed isoantibodies of similar specificity. On the other hand, 
Ab2 does not recognize cqrb/33-specific  antibodies produced by two Glanzmann thrombasthenia 
patients,  AF and LUC, who have developed isoantibodies with specificities distinct from that 
of the OG isoantibody.  Moreover, Ab2 does not recognize oqro/33-specific  antibodies developed 
by three representative patients with (autoimmune) thrombocytopenic purpura or six representative 
patients with alloimmune thrombocytopenias, nor does it bind to IgG from any of 13 nonimmunized 
individuals.  We have found that Ab2 also binds to selected protein ligands of Cqlb/33 namely, 
fibrinogen,  vitronectin, and von Willebrand factor, but not to other protein ligands or control 
proteins,  such a fibronectin,  type I collagen,  and albumin. The epitope(s) recognized by Ab2 
on each adhesive protein are either very similar or identical since each protein can inhibit the 
binding of Ab2 to any of the other proteins. The epitope on fibrinogen recognized by Ab2 resides 
in the B/3 chain, and is likely contained within the first 42 amino acids from the NH2 terminus. 
Since OG IgG inhibits fibrinogen binding to  O~llb~3,  the specificity of the OG idiotype defines 
a novel binding motif for the integrin OllIb/33 that is shared by fibrinogen,  vitronectin, and yon 
WiUebrand factor, but distinct from previously described RGD-containing sites on the fibrinogen, 
Ac~ chain or the fibrinogen "y chain COOH-terminal decapeptide site. Our findings reported 
here represent  an excellent example of molecular mimicry in which an antigen-selected,  IgG 
inhibitor of O~IIb/33 function shares a novel recognition sequence common to three physiologic 
protein ligands  of that receptor. 
T 
he integrin O~IIb/33 is probably  the most immunogenic 
protein complex on the surface of human platelets. This 
generalization is based on the fact that it is the most frequently 
identified target of human autoantibodies in immune-mediated 
thrombocytopenia and immune-mediated platelet  dysfunc- 
tion (1) and that oqro/33 bears no less than five amino acid 
polymorphisms that are responsible for a majority of cases 
of platelet-specific alloimmunization among Caucasians (1). 
In  addition,  patients  with  the  inherited abnormality  of 
O~IIb/33 known as Glanzmann thrombasthenia (GT) 1 tend to 
develop anti-c~ir~/33 antibodies (isoantibodies) after receiving 
blood transfusions to correct bleeding diatheses. Some of the 
isoantibodies react solely with the c~iro/33  complex (2), others 
are specific for either the CCiib (3) or the/33 subunits  (4, 5). 
1  Abbreviations used in this  ~per: AP, alkaline phosphatase; GT, Glanzmann 
thrombasthenia;  Vn, vitronectin; vWf, yon Willebrand factor. 
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antibodies most frequently encountered by the serology lab- 
oratory, they are of significant clinical and scientific interest 
since they can lead to a severe state of refractoriness to platelet 
transfusion therapy and because they generally recognize epi- 
topes on c~tro33 that are involved in the adhesive function of 
this integrin. 
We have recently defined the OG idiotype (Ishida, F., Y. 
Gruel, E. Brojer,  D. J.  Nugent, and T. J. Kunicki, manu- 
script submitted for publication) associated with IgG anti- 
bodies specific for the integrin B3 subunit produced by such 
a GT patient (OG) who suffered from persistent and often 
serious bleeding episodes  as a result of his disease (6). The 
frequency and severity of bleeding episodes in OG were far 
above the norm for this disease, presumably because this high 
titered, IgG antibody which proved to be in vitro an effec- 
tive inhibitor of transfused platelets and thereby rendered ther- 
apeutic platelet intervention ineffective  (4,  7). 
It is our contention that the characterization of the OG 
idiotype will lead to a better understanding of the mecha- 
nisms involved in immunization against the integrin cgiib33, 
both in the case of OG and in the case of other individuals, 
with or without GT. In this report, we use a highly specific, 
polyclonal anti-OG idiotype reagent (Ab2) to determine the 
distribution of antibodies bearing the OG idiotype among 
individuals immunized against olin,33 and normal volunteers. 
In addition, we provide evidence that Ab2 binds to epitopes 
common to  three adhesive  proteins recognized by otiib33, 
fibrinogen, vitronectin (Vn), and yon Willebrand factor (vWf). 
Materials  and Methods 
Human IgG.  The clinical history and laboratory findings of 
patient OG have been described (4, 7) (Ishida et al., manuscript 
submitted for publication). In Western blot assays  and an antigen 
capture enzyme-linked  immunoabsorbant assay,  we consistently  de- 
tect IgG in OG plasma that binds to free/33 (4). This IgG (Abl) 
completely blocks fibrinogen binding to c~lrbB3 and thus platelet 
aggregation induced by ADP, thrombin,  or other  physiologic 
agonists (4, 7). Other patients contributing to this study include 
three unrelated individuals  with GT."  patient ES, described  by Coiler 
et al. (2), has developed an IgG isoantibody that binds predomi- 
nantly to the cqroB3 complex and does not cross-react with cevB3; 
IgG from patient LUC (8) is predominantly reactive with Cenb  and, 
consequently, does not cross-react with cevB3; and IgG from pa- 
tient AF (5) binds equally well to both ~IIb~3 and czvB3 and has 
been found to recognize an epitope(s) localized within B3324-422 
(9). Additional patients include six individuals  who have developed 
plasma IgG Oqtb~3-specific  alloantibodies, namely, three with anti- 
Pl  ^1 antibodies (10, 11), GAS, KILO, and WHA; two with anti- 
Pen  b (12, 13) alloantibodies,  YuA and TRU; and one with anti-Pew 
antibodies, YuB (12); and three individuals  diagnosed  to have  chronic 
(autoimmune) thrombocytopenic purpura  who have developed 
33-specific autoantibodies, RA, GER,  and BER (14, 15). 
Comparative  Binding of  Human IgG Antibodies.  Established  proce- 
dures were used for purification of o~iroB3 (16) or cevB3 (17). The 
amount of IgG in plasma or purified IgG fractions which binds 
to o~vB3  or cereS3 integrins was measured  by ELISA. Briefly,  100 pl 
of 0.05 M sodium carbonate buffer, pH 9.6, containing 2 pg/ml 
of purified cxvB3 or c~lroB3 were added to each well of a microtiter 
plate, and plates were incubated at 4~  overnight to permit max- 
imal adsorption of antigen. The plates were blocked with PBS/ 
Tween and rinsed three times; to each well were added 50 #1 of 
test human plasma (diluted 1:100 in PBS/Tween) or purified IgG 
(50/~g/ml), and the plates were incubated for 2 h at ambient tem- 
perature. The wells  were washed  three times with PBS/Tween, 50/~1 
of alkaline phosphatase (AP)-conjugated goat anti-human IgG 
(heavy + light chain; Zymed Laboratories,  Inc., San Francisco,  CA) 
diluted 1:1,000 were added to each well, and plates were incubated 
at ambient temperature for 1 h. After five subsequent washes with 
PBS/Tween, the color reaction  was initiated, and the OD at 405 nM 
was recorded as described above. 
Purification of Abl.  IgG was isolated from OG plasma by am- 
monium sulfate  precipitation and DEAE cellulose  chromatography, 
as described (18), while Otnb•3  was purified from washed platelets 
according to the method of Fitzgerald et al. (16). cqrd33-specific 
antibodies were affmity-purified  by adsorption to Oqlb~3, coupled 
to CNBr-activated Sepharose 4B (1.5 mg antigen/ml beads; Phar- 
macia Fine Chemicals, Uppsala, Sweden). 2 ml of packed beads 
was incubated overnight at 4~  with 30 mg of OG IgG in 2 ml 
of 20 mM Tris, pH 7.4. Bound antibody was eluted by addition 
of 100 mM glycine, pH 3.0, and the eluate was neutralized by ad- 
dition of 1.5 M Tris, pH 8.8. Fab were prepared by digestion of 
affmity-purified  IgG with mercaptopapain (Sigma Chemical Co., 
St. Louis,  MO) in PBS containing 10 mM cysteine  and 2 mM ~, 
as described (14). Intact IgG and Fc fragments were removed by 
protein A-Sepharose  (Pharmacia  Fine Chemicals)  chromatography. 
Purity of Fab preparations was confirmed by SDS-PAGE. 
Preparation  ofRabM PolydonalAb2.  Fab fragments  of the purified 
OG IgG  specific for Oqlb/33 were used to immunize two New 
Zealand White rabbits. For primary immunizations, each rabbit 
was injected subcutaneously in the back with 50 #g of affmity- 
purified OG Fab emulsified in CFA. Booster injections (50/~g) 
were given in incomplete Freund's adjuvant on day 7, 14, 35, and 
every 2 wk thereafter. Sera were collected from ear arteries on day 
1, 21, and every 15 d thereafter. Sera were stored at 4~  before 
use. IgG was isolated from sera of immunized rabbits, as described 
above for human IgG, and adsorbed by successive passages over 
columns containing a 50-fold molar excess of normal human IgG 
plus IgM linked to Sepharose 4B (Pharmacia Fine Chemicals) a 
minimum of three times or until all detectable reactivity with iso- 
typic or allotypic determinants was removed. 
Specificity ofAb2for OG IgG.  50 pl of normal human IgG 
(Jackson ImmunoResearch  Laboratories, West Grove, PA) or affinity- 
purified OG IgG in 0.05 M sodium carbonate buffer, pH 9.6, was 
added to each well of a microtiter plate (Immulon II; Dynatech 
Laboratories, Inc., Alexandria, VA), and plates were incubated at 
4~  overnight. The wells were blotted dry, to each  well were added 
200/~1 of 67 mM NaHPO4, 67 mM Na2PO4, 150 mM NaC1, pH 
7.4 containing 0.05% Tween 20 (PBS/Tween), and plates were in- 
cubated for I h at ambient temperature to block remaining binding 
sites. After three rinses with PBS/Tween, 50 ~1 of rabbit Ab2 
(5 #g/ml in PBS/Tween) was added to each well, and plates were 
incubated for I h. The weUs were washed with PBS/Tween three 
more times, then to each well were added 50 pl of AP-conjugated 
goat anti-rabbit IgG (heavy + light chain; Zymed, Inc.), diluted 
1:1,000 in PBS/Tween, and plates were incubated for 1 h. After 
an additional five washes, the color reaction was initiated, and the 
OD at 405 nm for each well was recorded at intervals using an 
automated microphte  reader (EIA reader, model 255; Bio-Rad 
Laboratories, Richmond,  CA). 
ELISA Screen of Human lgG for 0(7, Id.  50 pl of a 10/~g/ml 
solution of murine monoclonal antibody HB43 (anti-human IgG 
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wells of a microtiter plate (Immulon II; Dynatech Laboratories, 
Inc.). Plates were then incubated either at ambient temperature 
for 3 h or at 4~  overnight to permit maximal adsorption of  added 
HB43, with comparable results. The wells were then rinsed six 
times with PBS/Tween. To block nonreacted surfaces, the wells 
were then incubated for 60 rain at ambient temperature  with 250 #1 
PBS/Tween containing 2% (wt/vol) BSA, and rinsed six times with 
PBS/Tween. Human plasmas or IgG preparations to be tested were 
first diluted 1:100 or 1:1,000 in PBS/Tween. 50/~1 of each human 
test sample was added to each well (in triplicate), and plates were 
incubated for 1 h at ambient temperature. The wells were rinsed 
six times with PBS/Tween, 50/~1 of affinity-purified  Ab2 (4/~g/ml) 
was added to each well, and plates were incubated for 1 h. The 
wells were then washed with PBS/Tween three times, to each well 
was added 50/~1 of  alkaline-phosphatase  conjugated  goat anti-rabbit 
IgG (Zymed, Inc.) diluted 1:1,000 in PBS/Tween, and plates were 
incubated for I h. After an additional five washes, the color reac- 
tion was initiated, and the OD at 405 nm of  each well was recorded 
in an EIA reader (Bio-Rad Laboratories) at appropriate intervals 
(nominally, at 30 min). 
Binding to Ab2 to Purified Proteins.  Human plasma fibronectin 
and type I collagen were purified as previously described (19, 20). 
Human plasma vitronectin was purified as described (21) and was 
a gift from Dr. Brunhilde  Felding-Haberman  (l.aJolla, CA). Human 
plasma vWf, human fibrinogen (fraction I-2), fragment X, frag- 
ment D100, and fragment E were purified as described (22, 23) and 
generously provided by Dr. Zaverio Ruggeri (La Jolla, CA). To 
adsorb antigen, 50/~1 of carbonate buffer containing the purified 
protein was added to each well of a microtiter plate, and plates 
were incubated  overnight  at 4~  The concentrations  of  each protein 
that enabled maximal adsorption were determined beforehand and 
were: 2/~g/ml type I collagen; 5/~g/ml fibrinogen; 10/~g/ml fibro- 
nectin; 4/~g/ml fragment D100; 3 #g/ml fragment E; 7.5/~g/ml 
fragment X; 2/~g/ml vitronectin; and 5/~g/ml vWf. The wells 
were blocked with PBS/Tween, and after three rinses with PBS/ 
Tween, the binding of Ab2 (50 #1 vol containing 0-50/~g/ml in 
PBS/Tween) was measured  as described above. In competition assays, 
25 #1 of PBS/Tween containing the inhibitory protein at 0.2, 1, 
2, 5, 10, 25, 50, or 100/~g/ml was added at the same time as Ab2, 
the mixtures were incubated for 2 h at ambient temperature, and 
the plates were processed as described above. 
To assess the effect  of selected fibrinogen-specific,  murine mono- 
clonal antibodies on the binding of Ab2 to fibrinogen, wells coated 
with fibrinogen,  as described  above, were then incubated  with 100/~1 
of  routine antibody IgG in PBS/Tween for 2 h at ambient tempera- 
ture. The wells were then rinsed three times, Ab2 (10/~g/ml in 
PBS/Tween) was added, the plates were incubated for an additional 
2 h, and the reactions were assessed as described above. Murine 
IgG was added at a concentration of 1, 2.5, 5, or 25 #g/ml. The 
murine antibodies developed and characterized by Dr. Z. Ruggeri 
and co-workers (24, 25) are: anti-RGDS (LJ-134B29; anti-Ao~566- 
580); anti-IkGDF (LJ-155Bg; anti-Ac~87-100); anti-L10  (LJ-Z-69/8; 
anti-q,400-411); and anti-BB (LJ-33.4; specific  for an unidentified 
epitope(s) in the NH2-terminal region). 
Western Blot.  The specificity  of the antifibrinogen activity of 
Ab2 was further analyzed by Western blot (18). SDS-PAGE was 
performed  as previously  described (18) using a Laemmli  buffer system 
and  10%  polyacrylamide resolving slab gels. Purified human 
fibrinogen (fractions I-2 and I-9), prepared as described (26) and 
generously provided by Dr. David Amrani (Milwaukee, WI), and 
fragment D100, were subjected to electrophoresis together with 
normal human Fab and OG Fab. Reduction was accomplished  by 
addition of 5% 2-mercaptoethanol. After dectrophoresis, proteins 
were transferred  to 0.2/~m pore-size nitrocellulose  membranes  (Bio- 
Pad Laboratories) in the following manner. Acrylamide gels and 
membranes were equilibrated in transfer buffer (192 mM glycine, 
25 mM "Iris, 20% methanol, pH 8.3), and transfer of proteins was 
accomplished at 30 V for 30 rain followed  by 60 V for 3 h at 4~ 
After transfer, the remaining active sites of the nitrocellulose  mem- 
brane were blocked by incubating the membrane in PBS/Tween 
containing 0.05% NaN3 and 1% nonfat dry milk. The membrane 
was then washed three times for 10 min each in PBS/Tween. The 
same buffer containing 1% nonfat dry milk was used to dilute the 
primary antibodies or the purified conjugated antibody. The mem- 
brane strips were incubated with the primary antibody, i.e., rabbit 
Ab2 or polyclonal  rabbit anti-human fibrinogen (Dako Corp., Car- 
pinteria, CA), overnight (16-20 h) at room temperature with con- 
stant, gentle, orbital agitation. Then, strips were washed  three times 
for 10 min and incubated with a 1:1,000 dilution of alkaline-phos- 
phatase conjugated goat antibodies against rabbit IgG (heavy + 
light chain; Zymed, Inc.). After 2-3 h and three additional washes, 
the binding of this antibody was revealed  by incubating the strips 
in freshly prepared substrate solution consisting of 66/~1 of a stock 
solution of nitroblue tetrazolium (50 mg/ml in 70% dimethyl- 
formamide) and 33 #1 of a stock solution of bromo-4-chloro-3- 
indolylphosphate  (50 mg/ml in 100% dimethyl-formamide)  in 10 ml 
of 100 mM Tris-HC1, 100 mM NaC1, 5 mM MgC12, pH 9.5. To 
stop color development, the membranes were rinsed in distilled 
water for 10 min and allowed to dry. 
Peptides.  Peptides were  synthesized using F-moc chemistry 
and an automated  peptide synthesizer  (MilliGen/Biosearch,  Burling- 
ton,  MA)  then purified by reverse-phase HPLC,  as previously 
described (27). 
Results 
Comparison of Human  IgG  that Bind c~ii~3.  Both OG 
and ES IgG bind weakly, if at all, to olv:/3 (Fig.  1), unlike 
AF IgG and each of the aUoantibodies  tested, namely GAS 
and KKO. Since OG IgG is known to bind to free :/3 in 
Western blot assays (4), two explanations for these findings 
are possible.  Either the OG epitope(s)  on :/3 is masked in 
the olv:/3 complex or there exist both :/3-reactive and c~iro:/3- 
restricted IgG antibodies. Because  the anti-:/3  eluted from 
Western blot membranes binds to O/lib:/3 on intact platdets, 
and antibodies eluted from intact platdets or purified O~IIb:/3 
bind solely to :t3 in subsequent Western blots (4), the latter 
explanation is not likely. The lack of binding of LUC IgG 
to 0l~:/3 is expected since it contains isoantibodies that pre- 
dominantly bind O~llb (3,  8).  Moreover,  the  difference  in 
binding of AF and OG (or ES) to  Cl~v:/3 is alSO consistent 
with a difference  in epitope location on :/3.  While AF is 
now known to bind to epitopes located within :/3 324-422 
(9), OG binding is predominantly to epitopes within :/3 7- 
52 (Honda, S., Y. Honda, and T. J. Kunicki, unpublished 
observation). 
Rabbit  Polyclonal Ab2.  After adsorption  with  pooled, 
normal human IgG plus IgM, Ab2 IgG binds to OG IgG 
but not to pooled normal human IgG or to any individual 
normal human IgG, and binding of Ab2 to OG IgG is in- 
hibited by purified Ofllb~3 in a dose-dependent manner (Fig. 
2).  Thus, Ab2 contains predominantly those antiidiotypic 
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Figure  1.  Binding of human  IgG to  33  integrins.  Purified  human 
oqro33 (m) or OtvB3 ([]) was adsorbed onto wells of a microtiter tray at 
identical concentrations (2/~g/ml). Plasmas (suffix "p") or IgG (all others) 
from a group of donors known to contain ~XirbB3-reactive  antibodies were 
allowed to incubate with antigen,  then bound human IgG was detected 
with rabbit anti-human IgG. Of the donors tested, IgG from ES, LUC, 
and the propositus OG binds e~chsively or much more strongly to cqrbB3, 
while IgG from AF, GAS, and KR.O binds  equally well to both O~llb~3 
and otv/~3. In each case, the mean  _+  SD is depicted (for oqn,B3, n  =  4; 
for ~v3s, n =  2). As a negative control, the lack of binding oflgG from 
normal subjects (C) is conspicuous (for Oqlb33, n =  10; for otvB3, n =  2). 
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Figure  2.  Reactivity of rabbit polyclonal Ab2. (A) Binding of Ab2 to 
OG IgG (solid circles) or a pool of normal human IgG (open circles) in an 
ELISA. OG IgG or normal IgG were adsorbed onto welts of microtiter 
trays. Bound Ab2 was detected by AP-conjugated  goat anti-rabbit IgG. 
The amount of IgG as antigen is indicated on the abscissa. (B) Competi- 
tive ELISA wherein the ability of purified oqrd~3 to inhibit the binding 
of Ab2  to  solid-phase Abl  is measured.  OG IgG was  used  at  either 
25 ng/well (open circles) or 50 ng/well (solid circles). Purified Ot.bB3 was 
added to the well at the same time as Ab2. Bound rabbit IgG was detected 
with AP-conjugated  goat anti-rabbit IgG. The concentration  of O/llb~3 
used is indicated  on the abscissa. 
antibodies that are classified Ab23, i.e., those that mimic an- 
tigen epitopes and block the binding of Abl to antigen. 
To determine the extent to which the OG idiotype is used 
by  oLlro33-specific antibodies  from  other  individuals,  we 
tested the binding of Ab2 to IgG in sera, plasmas, and IgG 
preparations from nonimmunized  volunteers and persons who 
have been previously determined to have developed antibodies 
against c~in,133  as a result of auto-, allo-, or isoimmunization 
(Fig. 3 A). From this preliminary screening, it is evident that 
Ab2 binds to a restricted subset of human antibodies reactive 
with oeiib33, i.e., only those antibodies generated by certain 
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Figure  3.  (A) Binding of Ab2 to human IgG. Plasma IgG from donors indicated on the abscissa was specifically captured by adsorption  to murine 
mAb HB43  (anti-human IgG Fc)-coated microtiter trays. These donors  included:  13 nonimmunized volunteers  (C); four patients  with Glanzmann 
thrombasthenia  (GT) who have documented  alrdSs-reactive isoantibodies  (OG, AF, LUC, and ES); six individuals known to have developed a,bB3- 
reactive alloantibodies as a result of neonatal alloimmunization of posttransfusion  purpura  (NATP/PTP) (KRO, YuA, YuB, WHA, TRU, GAS); and 
three ITP patients documented to have cqroBs-reactive  autoantibodies  (GER, RA, and BER). The binding of Ab2 to captured human IgG is expressed 
as optical density recorded at  405 nm (ordinate).  All values represent mean (bar)  •  SD (for controls,  n  =  13; all others,  n  =  4). The binding of 
Ab2 to IgG from each donor was tested on at least two occasions, with equivalent results. (B) Lack of  binding of Ab2 to antigen-captured  Abl. Microtiter 
trays were coated with a]rd33. The binding of human IgG to solid-phase oqro/83 was detected by the subsequent  binding of rabbit  anti-human IgG 
(11). In parallel wells, bound human IgG was detected by rabbit anti-OGld (Ab2) (D). Human antibody  sources are as described in (.4). OG samples 
are: (1 and 2) two preparations  of OG IgG; (3) OG plasma;  and (4) affinity-purified OG IgG (adsorbed by and eluted  from oqr.33). Mean  +_  SD 
is depicted  (for control, n  =  4; for all others,  ,  =  2). 
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Figure 4.  (A) Effect of peptides on OG IgG binding to ~XXXbBS.  The effect on OG IgG binding of increasing concentrations (abscissa) of the pep- 
rides R.GDW (0) or L10 (O) was measured.  The percent  inhibition of binding of OG IgG (ordinate)  in the presence of increasing  peptide (/~M) 
(abscissa) is plotted. As a positive control, the inhibition of binding of murine mAb OPG2 by RGDW was also tested (I). Values represent  mean 
+  SD (n  =  4).  (B) Inhibition by OG IgG of the binding of selected routine mAb to (Xll~3. The binding of murine mAbs OPG2 (O),  7E3 (0), 
anti-LIBS2  (m), AP2(A), SZ21 (0),  and AP5 (I-I) in the presence and absence of OG IgG was determined. The percent inhibition of binding of 
each mAb (ordinate) in the presence of increasing OG IgG (/~g/ml)  (abscissa) is plotted. Values represent mean  _+  SD (n  =  4). 
individuals with the hereditary disorder  GT. The presence 
of the OG idiotype (OG and ES positive; AF, LUC, and re- 
maining donors negative) correlates well with the observed 
binding properties of IgG from these donors (Fig. 1). Thus, 
the OG idiotype-positive  individuals,  OG and ES, are the 
sole subjects whose IgG antibody binds to 83 but also dis- 
tinguishes  cx[roB3 from (Xv~3. 
When patient IgG is permitted to bind to c~irJ33-coated 
microtiter plates  (Fig.  3  B),  significant  levels of  O/IIb~3 ~ 
specific antibody are bound, as detected with rabbit  anti- 
human IgG (solid bars). However, bound OG idiotype-positive 
IgG (OG or ES IgG) cannot be detected by the rabbit  an- 
tiidiotype Ab2, presumably because  Ab2B antiidiotypes, which 
are the predominant component of this antiidiotype reagent, 
cannot access the specific paratopes once they are in contact 
with antigen. However, OG IgG eluted from otiib~3-coated 
microtiter plates, is strongly bound by Ab2 in subsequent 
ELISA (4). 
Peptide and MAb Competition.  The binding of OG IgG 
(Abl) to o~3  is not inhibited by either the peptide RGDW 
or the "y-chain decapeptide L10 (Fig. 4 A), even when pep- 
tide concentrations as high as 2 mM were used. As a control, 
specific inhibition of mAb OPG2 by KGDW was observed 
(IDs0 =6 #M). Of six Oqlb/33-specific mAb tested, OG IgG 
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Figure 5.  Binding of Ab2 to selected human adhe- 
five proteins. Depicted is the binding of Ab2 (0) or 
IgG from  nonimmunized  rabbits  (O)  to  purified 
human (A) fibrinogen; (/3) yon Wilhbrand factor; (C) 
vitronectin; (/9) fibronectin;  or (E) type I collagen. 
The concentration of Ab2 or nonimmune IgG 0,g/ml) 
added is indicated on the abscissa. In E, the two lines 
are superimposable.  Values depicted are the mean of 
duplicate determinations for a single representative 
experiment. 
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Figure 6.  Competitive binding of adhesive proteins. The binding of 
Ab2 to (.4) iibrinogen; (B) yon Willebrand  factor; or (C) vitronectin  was 
measured  in the presence of increasing  amounts of vitronectin (0), 
fibrinogen (B), yon Willebrand factor (O), or type I collagen (A). The 
concentration of inhibitor protein (#g/ml) is indicated on the abscissa. 
Values represent the mean of duplicate determinations in a single represen- 
tative experiment. 
strongly inhibited the binding of only 7E3 or OPG2 (Fig. 
4 B), two IgG mAb known to bind to distinct sites within 
the fibrinogen recognition pocket of Otlro33. 7E3 and OPG2 
are both complex-dependent mAb. As controls, no inhibi- 
tion of the binding of the complex-specific mAb AP2 (epi- 
tope unknown), AP5 (anti-/331-5), SZ21 (anti-3327-32),  or 
LIBS2 (anti-/33602-690) was observed. Although not tested 
here, ES IgG has also been shown to significantly inhibit the 
binding of 7E3 to ~xlro/33 (2). 
As shown in Fig. 5, Ab2 also binds to fibrinogen, vWf 
and vitronectin but not to fibronectin, collagen  type I, or 
the control protein, albumin. The binding of Ab2 to any 
one of these three adhesive proteins is completely inhibited 
by either of the remaining two (Fig. 6), suggesting that Ab2 
recognizes cross-reactive or identical epitopes on these three 
proteins. 
We previously determined that  the binding of Abl  to 
o+t~l~,.+ could not be inhibited by KGD-containing peptides, 
such as KGDW, or the carboxyl-terminal decapeptide of the 
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Figure 7.  (A) Effect ofmurine monoclonal anti-KGDS (@), and-RGDF 
(I), anti-L10 (A), or anti-B3 chain (O) on the binding of Ab2 to solid- 
phase intact fibrinogen. The concentration of inhibitor monoclonal anti- 
body (#g/ml) is indicated on the abscissa. (B) Comparative binding of 
Ab2 to intact fibrinogen (@), fragment X (.), fragment D (A), and frag- 
ment E (O). The concentration of Ab2 added (#g/ml) is indicated on 
the abscissa. 
fibrinogen gamma A  chain (L10) (Fig.  4).  Likewise,  the 
binding of Ab2 to fibrinogen is not inhibited by any of three 
murine monodonal antibodies specific for the three putative 
integrin binding sites on this molecule, namely RGDS and 
RGDF on the Ac~ chain or LIO (Fig. 7 A). These findings 
are supported by a comparison of the binding of Ab2 to in- 
tact fibrinogen and its major plasmin-derived fragments. Thus, 
in comparison to intact fibrinogen, Ab2 binds less strongly 
to fragment X and not at all to fragment D or fragment E 
(Fig. 7 B). Finally, by Western blot assay, Ab2 binds prefer- 
entially to a protein band whose electrophoretic mobility is 
consistent with that of the B/3 chain (Fig.  8). 
Since the differential binding of Ab2 to fibrinogen frag- 
ments and the results ofimmunoblot assays suggest that Bfl15- 
42 might participate in epitopes recognized by Ab2, we tested 
the ability of three overlapping B3 peptides, B/315-28, B/324- 
33, and B332-42, to inhibit binding of Ab2 to either fibrin- 
ogen or vitronectin. None of the three peptides inhibits Ab2 
binding even at concentrations as high as 2 mM (data not 
shown). 
2264  Further Characterization  of the Thrombasthenia-related  Idiotype OG Figure  8.  Binding of Ab2 to OG Fab and individual fibrinogen chains 
as determined by Western blot assay. Proteins were reduced and separated 
on polyaeryhmide slab gels and transferred to nitrocellulose membranes. 
The following proteins (left to right) were tested:  10/zg purified human 
fibrinogen fraction I-2; 10 ttg human fibrinogen fragment D100 (D); and 
10 ~g human fibrinogen fraction I-9. The left panel depicts a membrane 
incubated with Ab2. The right panel depicts a membrane incubated with 
rabbit polyclonal anti-human fibrinogen. To the right are indicated the 
fibrinogen bands that represent intact Acx, BE, and "y chains,  as well as 
the major plasmin-generated fragments of the Acx chain, designated Acx/6, 
Aa/7,  Ac~/8,  Acx/9,  and Acx/10. 
Discussion 
Since the initial description of the idiotype network, there 
has been a great deal of interest in the potential role of this 
network in the regulation of the immune response and in 
the exploitation of antiidiotypes for the development of vac- 
cines or inhibitors of the immune response, because certain 
antiidiotypes bear the "internal images" of the primary an- 
tigen (28). Yet another interesting and practical application 
of antiidiotypes stems from the capacity of antiidiotypes to 
mimic functional protein recognition site(s) of the primary 
antigen. Anti-Id antibodies are classified into four major cat- 
egories, Ab2cz, -fl, -% and -e, but only Ab2fl, which bind 
to the paratope (28) of Abl and carry the internal image of 
the antigen, or Ab2% which recognize antigen combining- 
site-associated  idiotopes, are able to interfere with the inter- 
action of Abl with antigen. In this study, we conclude that 
Ab2 contains predominantly Ab2fl and/or Ab2y, because 
purified CXnbB3  inhibits the binding of Ab2 to OG IgG, and 
Ab2 is precluded from binding to Abl when Abl is bound 
to OeHbfl3. This conclusion is supported by the finding that 
Ab2 binds strongly to an epitope(s) common to three physi- 
ologic ligands of r  i.e.,  fibrinogen, vWf,  and Vn. 
Since OG isoantibody binds to B3 and inhibits ADP- or 
thrombin-induced  plat,  let aggregation, it is likely that it binds 
close to or at recognition site(s) on f13 for fibrinogen. There 
are two loci on f13 that have been implicated as fibrinogen 
contact sites. The first,  flanking Asp119, is thought to en- 
gage the RGDS sequence of the fibrinogen Acx chain (29, 
30).  The  second, encompassing amino acids  209-222,  is 
thought to interact with a different site on fibrinogen (31). 
Our results indicate that the OG isoantibody (Abl) does not 
bind to either of these loci. First, neither RGD-containing 
peptides nor our murine monoclonal antibody OPG2 (32), 
which contains an P,  YD sequence and binds to the first rec- 
ognition site on ~3, inhibit the binding of OG isoantibody. 
Second,  our murine monoclonal IgM antibody AP6 (33), 
which binds to the sequence ~3 209-222, also fails to inhibit 
the binding of OG isoantibody. Third, by comparing the 
binding  of  OG  isoantibody  to  recombinant  human  ~3, 
Xenopus/33, and several chimeras of human 133:Xenolous~3, 
we have found that the epitope recognized by OG isoanti- 
body is determined by sequences within residues 7-53 of ~3 
(S. Honda, Y. Honda, and T. J. Kunicki, unpublished obser- 
vation). 
The fact that the putative adhesive sequences of fibrinogen, 
i.e., RGDS (Acx 572-575) or L10 (decapeptide "y402-411) are 
not involved is supported by ELISA results wherein Ab2 binds 
to fibrinogen fragment X  which does not contain the o~ 
COOH-terminal P,  GDS  site, and Ab2 binding to human 
fibrinogen is not inhibited by murine monodonal antibodies 
specific for either Aol 566-580 (encompassing RGDS), Acx 
87-100 (encompassing RGDF),  or the 3' COOH-terminal 
decapeptide. Thus, the epitopes within fibrinogen recognized 
by  Ab2  are  distinct  from  the  RGD  sequences.  We  find 
common epitopes in Vn and vWf. By ELISA, the binding 
of Ab2 to Vn or vWf is stronger than that observed with 
fibrinogen, and the epitopes on Vn and vWf are similar if 
not identical to those fibrinogen, since any one of these pro- 
teins is able to completely inhibit the binding of Ab2 to the 
other two. Other RGD-containing ligands, namely, collagen 
type I and fibronectin, are not recognized by Ab2, consistent 
with the conclusion that Ab2 binds to RGD-independent 
sequences. 
Without further localization of the cross-reactive regions 
on the fibrinogen B3 chain, Vn, or vWf, it is not possible 
to precisely identify the epitopes for Ab2 solely by sequence 
homologies even if a few homologous short acid sequences 
are present. We will use a number of approaches to further 
localize the epitopes in question, including screening of random 
peptide libraries to find sequences that bind with high affinity 
to Ab2 and testing of additional proteolytic fragments of the 
fibrinogen B3  chain  or  well-defined fibrinogen variants. 
Nonetheless, our results,  in light of the fact that OG IgG 
inhibits platelet aggregation and fibrinogen binding and Ab2 
mimics the primary antigen, support the hypothesis that the 
Bfl chain is involved in the fibrinogen binding to platelet 
OelroB3 in a manner that has not yet been characterized. 
Ab2 reacts solely with OG isoantibodies (Abl) and czlr~33- 
specific isoantibodies from a second GT patient ES. In the 
limited comparison of four GT patient isoantibodies conducted 
2265  Gruel et al. in this study, ES IgG and OG IgG have the most similar 
specificities, with respect to Oqibl33 and oLv133. On the other 
hand, the two idiotype-negative IgG isoantibodies, from pa- 
tients AF and LUC, exhibit specificities different from one 
another and from ES or OG IgG. Thus, it is not surprising 
that the antiidiotype reagent can distinguish ES and OG IgG 
from the remaining two isoantibodies.  In addition, Ab2 never 
binds  to IgG from nonimmunized volunteers or to other 
c~Ird33-specific human IgG antibodies that were generated 
through different immune mechanisms, e.g., alloimmuniza- 
tion or autoimmunity. 
The finding that Ab2 binds to ES IgG indicates that these 
two unrelated GT patients have independently generated an- 
tibodies of similar specificity which share a common idio- 
type. It has not been logistically feasible to measure direct 
competition between OG IgG and ES IgG since that would 
require substantial  quantities of affinity-purified, labeled IgG, 
and these human antibodies are a limited resource. Additional 
evidence that ES and OG share the OG idiotype derives from 
the observation of Coller et al. (2) that ES IgG blocks the 
binding to c~iro/33 of the mAb 7E3.  In this study, we fur- 
ther establish  a dose relationship between ES IgG and OG 
IgG by showing that the latter also inhibits binding of 7E3 
to oelrol33. Moreover, we show that OG IgG also blocks the 
binding of our mAb OPG2. 7E2 and OPG2 are effective in- 
hibitors of fibrinogen binding to human platelets, and 7E3 
is the first mAb of its kind to be tested in humans in vivo, 
as an inhibitor of thrombus formation (34, 35). The epitope(s) 
recognized by 7E3,  OPG2, ES IgG, and OG IgG are obvi- 
ously of biological and clinical relevance, and are at least spa- 
tially related. 
Since Ab2 binds to the BB chain of fibrinogen, our study 
raises the possibility that a site(s), likely located within BB1- 
42,  makes contact with a recognition site on/33,  one that 
is defined by the OG epitope(s). Although there has not yet 
been any report of an interaction of the fibrinogen Bfl chain 
with r  or any other integrin,  Hamaguchi et al.  (36) 
have demonstrated that platelet spreading on fibrin is medi- 
ated by a site within Bfl15-42.  The receptor on endothelial 
cells that recognizes this site is bdieved to be a 130-kD sur- 
face protein not related to the integrins (37). We found that 
three overlapping peptides  representing sequences within 
Bfl15-42 had no effect on the binding of Ab2 to fibrinogen 
or vitronectin. However, this negative result does not con- 
clusively rule out that the epitope is present in this region 
of the Bfl chain, since the true epitope may be more complex 
than a simple linear sequence. Further studies are clearly war- 
ranted. 
The OG idiotype is the first idiotype to be described that 
is associated with human IgG inhibitors of c~iibfl3 function. 
Since the antibodies bearing this idiotype bind so closely to 
the ligand recognition pocket of c~ird33, it is not unexpected 
that antiidiotypic antibodies should bind to ligands that in- 
teract with this recognition pocket. However, it is truly seren- 
dipitous and significant that each of the molecular interac- 
tions involved in this idiotype network, i.e., binding of OG 
idiotype to oqrd33, OG idiotype to antiidiotype, and anti- 
idiotype to protein ligands, is mediated by a protein recogni- 
tion motif that is independent of any ligand:c~abfl3 interac- 
tion yet defined. Our findings represent an excellent example 
of the manner in which the characterization of the molec- 
ular basis of an immune response and the underlying idio- 
type network can substantially improve our understanding 
of biologically relevant protein:protein recognition mech- 
anisms. 
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